HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For instance, vorinostat, which is marketed under the name Zolinza® by Merck, is a potent HDAC inhibitor for treating cutaneous T-cell lymphoma but has been shown to cause bone loss during clinical trials of multiple myeloma [32].